Sugi Predict

Sugi Predict / Targets / KLK3

KLK3

Prostate-specific antigen · P07288 · KLK3 on Sugi Atlas →

3,939 patent compounds predicted against KLK3, 2,706 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2571839 SCHEMBL2571839 0.66 9/20
SCHEMBL1855101 SCHEMBL1855101 0.67 8/20
SCHEMBL1853581 SCHEMBL1853581 0.61 8/20
SCHEMBL2568841 SCHEMBL2568841 0.64 7/20
SCHEMBL2567843 SCHEMBL2567843 0.67 6/20
SCHEMBL2561567 SCHEMBL2561567 0.56 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL9121731) 0.53 6/20
SCHEMBL2551230 SCHEMBL2551230 0.52 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL9123032) 0.44 6/20
SCHEMBL11318137 SCHEMBL11318137 0.48 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL9124771) 0.46 4/20
SCHEMBL1605623 SCHEMBL1605623 0.52 3/20
SCHEMBL7370741 SCHEMBL7370741 0.48 3/20
SCHEMBL6871922 SCHEMBL6871922 0.47 3/20
SCHEMBL7143763 SCHEMBL7143763 0.47 3/20
Bromide Bromide (SCHEMBL6507643) 0.47 3/20
SCHEMBL3538604 SCHEMBL3538604 0.45 3/20
SCHEMBL1862123 SCHEMBL1862123 0.45 3/20
SCHEMBL3050885 SCHEMBL3050885 0.44 3/20
SCHEMBL6040694 SCHEMBL6040694 0.41 3/20

Clinical trials — most relevant to KLK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA PHASE1/PHASE2RECRUITING
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer PHASE2COMPLETED
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy PHASE2COMPLETED
Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer PHASE2WITHDRAWN
Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy PHASE2COMPLETED
Sequential Vaccinations in Prostate Cancer Patients PHASE1/PHASE2COMPLETED
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer PHASE2COMPLETED
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations PHASE2COMPLETED
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer PHASE1/PHASE2NOT_YET_RECRUITING
Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease PHASE1/PHASE2COMPLETED
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21 PHASE1COMPLETED
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population nanRECRUITING
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer nanCOMPLETED
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen) nanENROLLING_BY_INVITATION
A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine nanCOMPLETED
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants nanCOMPLETED
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. nanCOMPLETED
Improved Prostate Cancer Diagnosis - Combination of Rapid Prebiopsy Magnetic Resonance Imaging and Biomarkers nanUNKNOWN
Investigation of Three Biomarkers for the Detection of Prostate Cancer nanRECRUITING
Cancer DNA Detection in Blood and Urine nanCOMPLETED
Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence nanCOMPLETED
Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer nanACTIVE_NOT_RECRUITING
Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity nanRECRUITING
Men at High Genetic Risk for Prostate Cancer nanRECRUITING
Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome nanACTIVE_NOT_RECRUITING
Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial nanUNKNOWN
Prostate Cancer Biobank nanACTIVE_NOT_RECRUITING
Prostate Cancer Antigen 3 (PCA-3) Gene Project nanCOMPLETED
Stockholm3 Validation Study in a Multi-Ethnic Cohort nanCOMPLETED
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KLK3 binder may also engage these)

ProteinNameSimilarity
P33619 — 1.000 P33619 →
KLK2 Kallikrein-2 1.000 landscape →
P09582 — 0.998 P09582 →
Q6DT45 — 0.998 Q6DT45 →
Q07276 — 0.995 Q07276 →
Q28773 — 0.993 Q28773 →
Q76B45 — 0.993 Q76B45 →
KLK1 Kallikrein-1 0.992 landscape →
P09650 — 0.989 P09650 →
P56435 — 0.989 P56435 →
KLK13 Kallikrein-13 0.989 landscape →
P97592 — 0.989 P97592 →
P36369 — 0.989 P36369 →
A7WPL7 — 0.988 A7WPL7 →
P50341 — 0.987 P50341 →
P36368 — 0.987 P36368 →
KLK7 Kallikrein-7 0.987 landscape →
P36373 — 0.987 P36373 →
P21845 — 0.986 P21845 →
TPSAB1 Tryptase beta-1 0.985 landscape →
Q5FBW2 — 0.985 Q5FBW2 →
P36374 — 0.985 P36374 →
P50342 — 0.984 P50342 →
Q03238 — 0.984 Q03238 →
P21842 — 0.984 P21842 →
TPSB2 Tryptase beta-2 0.984 landscape →
KLK6 Kallikrein-6 0.984 landscape →
P50343 — 0.984 P50343 →
P50339 — 0.984 P50339 →
P79204 — 0.983 P79204 →